Display options
Cite
Gentile F, Deriu MA, Barakat K, et al. A Novel Interaction Between the TLR7 and a Colchicine Derivative Revealed Through a Computational and Experimental Study. Pharmaceuticals (Basel). 2018;11(1)doi: 10.3390/ph11010022.
Gentile, F., Deriu, M. A., Barakat, K., Danani, A., & Tuszynski, J. (2018). A Novel Interaction Between the TLR7 and a Colchicine Derivative Revealed Through a Computational and Experimental Study. Pharmaceuticals (Basel, Switzerland), 11(1), . https://doi.org/10.3390/ph11010022
Gentile, Francesco, et al. "A Novel Interaction Between the TLR7 and a Colchicine Derivative Revealed Through a Computational and Experimental Study." Pharmaceuticals (Basel, Switzerland) vol. 11,1 (2018). doi: https://doi.org/10.3390/ph11010022
Gentile F, Deriu MA, Barakat K, Danani A, Tuszynski J. A Novel Interaction Between the TLR7 and a Colchicine Derivative Revealed Through a Computational and Experimental Study. Pharmaceuticals (Basel). 2018 Feb 16;11(1). doi: 10.3390/ph11010022. PMID: 29462934; PMCID: PMC5874718.
Copy Download .nbib Format: NLM
Share it on

Pharmaceuticals (Basel). 2018 Feb 16;11(1). doi: 10.3390/ph11010022.

A Novel Interaction Between the TLR7 and a Colchicine Derivative Revealed Through a Computational and Experimental Study.

Pharmaceuticals (Basel, Switzerland)

Francesco Gentile, Marco A Deriu, Khaled Barakat, Andrea Danani, Jack Tuszynski

Affiliations

  1. Department of Physics, University of Alberta, AB T6G 2E1 Edmonton, Canada. [email protected].
  2. Istituto Dalle Molle di Studi Sull'intelligenza Artificiale (IDSIA), Scuola Universitaria Professionale della Svizzera Italiana (SUPSI), Università della Svizzera Italiana (USI), CH-6928 Manno, Switzerland. [email protected].
  3. Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, AB T6G 2H1 Edmonton, Canada. [email protected].
  4. Istituto Dalle Molle di Studi Sull'intelligenza Artificiale (IDSIA), Scuola Universitaria Professionale della Svizzera Italiana (SUPSI), Università della Svizzera Italiana (USI), CH-6928 Manno, Switzerland. [email protected].
  5. Department of Physics, University of Alberta, AB T6G 2E1 Edmonton, Canada. [email protected].
  6. Department of Mechanical and Aerospace Engineering, Politecnico di Torino, 10129 Torino, Italy. [email protected].
  7. Department of Oncology, University of Alberta, AB T6G 1Z2 Edmonton, Canada. [email protected].

PMID: 29462934 PMCID: PMC5874718 DOI: 10.3390/ph11010022

Abstract

The Toll-Like Receptor 7 (TLR7) is an endosomal membrane receptor involved in the innate immune system response. Its best-known small molecule activators are imidazoquinoline derivatives such as imiquimod (R-837) and resiquimod (R-848). Recently, an interaction between R-837 and the colchicine binding site of tubulin was reported. To investigate the possibility of an interaction between structural analogues of colchicine and the TLR7, a recent computational model for the dimeric form of the TLR7 receptor was used to determine a possible interaction with a colchicine derivative called CR42-24, active as a tubulin polymerization inhibitor. The estimated values of the binding energy of this molecule with respect to the TLR7 receptor were comparable to the energies of known binders as reported in a previous study. The binding to the TLR7 was further assessed by introducing genetic transformations in the TLR7 gene in cancer cell lines and exposing them to the compound. A negative shift of the IC50 value in terms of cell growth was observed in cell lines carrying the mutated TLR7 gene. The reported study suggests a possible interaction between TLR7 and a colchicine derivative, which can be explored for rational design of new drugs acting on this receptor by using a colchicine scaffold for additional modifications.

Keywords: TLR7; colchicine; imiquimod; innate immune system; off-target interaction

Conflict of interest statement

The authors declare no conflict of interests.

References

  1. Molecules. 2016 Oct 15;21(10 ): - PubMed
  2. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10495-9 - PubMed
  3. Nucleic Acids Res. 2000 Jan 1;28(1):235-42 - PubMed
  4. Oncogene. 2008 Jan 7;27(2):190-9 - PubMed
  5. J Leukoc Biol. 2013 Jun;93(6):847-63 - PubMed
  6. J Chem Theory Comput. 2013 Sep 10;9(9):3878-88 - PubMed
  7. J Comput Chem. 2004 Jul 15;25(9):1157-74 - PubMed
  8. Curr Top Med Chem. 2017;17 (22):2538-2558 - PubMed
  9. Proc Natl Acad Sci U S A. 2003 May 27;100(11):6646-51 - PubMed
  10. J Interferon Cytokine Res. 2012 Jun;32(6):254-68 - PubMed
  11. JAKSTAT. 2013 Jan 1;2(1):e23011 - PubMed
  12. Nature. 2004 Mar 11;428(6979):198-202 - PubMed
  13. Front Pharmacol. 2017 May 31;8:304 - PubMed
  14. Protein Sci. 2009 Aug;18(8):1684-91 - PubMed
  15. Nature. 2014 Jan 23;505(7484):495-501 - PubMed
  16. Chem Biol Drug Des. 2014 Jun;83(6):656-65 - PubMed
  17. J Clin Invest. 2012 Nov;122(11):4118-29 - PubMed
  18. Protein Sci. 1993 Sep;2(9):1511-9 - PubMed
  19. Int Immunol. 2005 Jan;17(1):1-14 - PubMed
  20. PLoS One. 2014 Mar 20;9(3):e92146 - PubMed
  21. Immunity. 2016 Oct 18;45(4):737-748 - PubMed
  22. Science. 2013 Mar 22;339(6126):1426-9 - PubMed
  23. J Mol Model. 2011 Jan;17(1):27-36 - PubMed
  24. J Chem Theory Comput. 2012 Sep 11;8(9):3314-21 - PubMed
  25. Molecules. 2015 May 08;20(5):8316-40 - PubMed
  26. PLoS Pathog. 2012;8(8):e1002841 - PubMed
  27. Curr Opin Pharmacol. 2012 Aug;12(4):510-8 - PubMed
  28. Nature. 2012 Mar 28;483(7391):570-5 - PubMed
  29. Clin Cancer Res. 2005 Jan 1;11(1):7-11 - PubMed
  30. Oncologist. 2008 Aug;13(8):859-75 - PubMed
  31. Expert Opin Investig Drugs. 2013 Jan;22(1):149-59 - PubMed
  32. Front Immunol. 2014 Sep 25;5:461 - PubMed
  33. PLoS One. 2017 Aug 10;12 (8):e0182022 - PubMed
  34. J Med Chem. 2006 Feb 9;49(3):947-54 - PubMed
  35. Science. 2013 Mar 29;339(6127):1546-58 - PubMed
  36. J Oncol. 2012;2012:103298 - PubMed
  37. J Comput Chem. 2005 Dec;26(16):1752-80 - PubMed
  38. Shock. 2009 Nov;32(5):484-90 - PubMed
  39. Oncoimmunology. 2012 Mar 1;1(2):227-228 - PubMed
  40. Proteins. 2004 May 1;55(2):383-94 - PubMed
  41. Pharm Res. 2012 Nov;29(11):2943-71 - PubMed
  42. J Comput Chem. 2008 Jul 30;29(10):1693-8 - PubMed

Publication Types